Welcome to our dedicated page for EVTCY news (Ticker: EVTCY), a resource for investors and traders seeking the latest updates and insights on EVTCY stock.
Evotec SE (symbol: EVTCY) is a life science company based in Hamburg, Germany, with a unique business model focused on discovering and developing highly effective therapeutics. The company operates globally with over 5,000 employees and has strategic activities in neurology, oncology, metabolic, and infectious diseases. Evotec's multimodality platform combines innovative technologies, data, and science to create a world-leading co-owned pipeline for innovative therapeutics. The company collaborates with top pharmaceutical companies, biotech firms, academic institutions, and other healthcare stakeholders to deliver cutting-edge pharmaceutical products.
News
Rhea-AI Summary
Evotec reported financial results for fiscal year 2023, meeting updated guidance. The company announced a priority reset to focus on profitable growth, with adjustments expected to drive annualized EBITDA improvement over €40 million. Despite challenges, group revenues increased by 4% to €781.4 million, with Just - Evotec Biologics revenue up 111%. Adjusted Group EBITDA was €66.4 million. Strategic partnerships with Bristol Myers Squibb and Janssen, new collaborations, CEO transition, and approval of targets by SBTi were highlighted. Evotec plans to update mid-term forecast with H1 2024 results, expecting double-digit revenue growth and reduction in unpartnered R&D expenses. The company aims for sustainable and profitable growth, with a priority reset to streamline operations and enhance profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Evotec SE appoints Dr. Christian Wojczewski as the new Chief Executive Officer, effective July 1, 2024. Dr. Wojczewski brings over 20 years of experience in management positions, most recently as CEO of Mediq and at Linde Healthcare. The appointment follows an extensive selection process. The current Interim CEO, Dr. Mario Polywka, will retire at the end of June.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Evotec SE will announce its financial results for 2023 on April 24, 2024, and hold a conference call to discuss the results and provide an update on its performance. The conference call will be held in English at 3.00 pm CEST. Webcast and phone details are provided for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Evotec appoints Aurélie Dalbiez as Chief People Officer, emphasizing a focus on people strategy, culture, and employee engagement. With over 25 years of HR leadership experience, Aurélie's role highlights Evotec's commitment to investing in its workforce and creating an inclusive work environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Evotec SE and Claris Ventures announce an acceleration framework to streamline programs from Claris's portfolio companies into the clinic. Evotec's integrated platform will provide full range of pre-clinical and clinical development and manufacturing capabilities to Claris's biotech companies. The successful collaboration between Evotec and Claris's portfolio company IAMA Therapeutics has led to an agreement that will benefit other portfolio companies as well.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Evotec SE's subsidiary, Just - Evotec Biologics, has expanded its relationship with Advanced BioScience Laboratories, Inc. to develop a third broadly neutralising antibody (bNAb) against HIV. The collaboration aims to provide large-scale cGMP manufacturing campaigns for the bNAb and a previously developed bNAb for a Phase I clinical study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Evotec SE is holding a conference call to provide a business update and a statement on its commitment to corporate governance standards. The call will feature the Chairwoman of Evotec's Supervisory Board, Prof. Iris Löw-Friedrich, and CEO Dr. Mario Polywka, discussing the company's strategy, recent market developments, and unchanged views on Guidance 2023 and the 2025 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Evotec SE (EVT) collaborates with the Crohn's & Colitis Foundation's IBD Therapeutics Incubator to advance drug discovery for inflammatory bowel disease (IBD). The collaboration focuses on developing innovative drug targets addressing fibrosis and impaired intestinal barrier function. Evotec's end-to-end integrated R&D platform will be utilized to translate groundbreaking basic research into medical innovations for IBD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Evotec SE (EVT) and Owkin Announce A.I.-Powered Collaboration in Oncology, Immunology, and Inflammation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Evotec SE (EVT) announces CEO Dr. Werner Lanthaler's resignation for personal reasons. Dr. Mario Polywka to serve as interim CEO. The company confirms its 2023 guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
Where is Evotec SE based?
Evotec SE is based in Hamburg, Germany.
What is Evotec SE's business model?
Evotec SE focuses on discovering and developing highly effective therapeutics.
How many employees does Evotec SE have?
Evotec SE operates globally with over 5,000 employees.
What are Evotec SE's strategic activities?
Evotec SE has strategic activities in neurology, oncology, metabolic, and infectious diseases.
Who does Evotec SE collaborate with?
Evotec SE collaborates with top pharmaceutical companies, biotech firms, academic institutions, and other healthcare stakeholders.
EVTCY